5-PAHSA
Based on 1 Customer Validation
5-PAHSA increases insulin sensitivity, and has orally active anti-inflammatory and neuroprotective effects in mice HFD-induced diabetes mice. 5-PAHSA can be used for research of neurological dysfunction in diabetics.
For research use only. We do not sell to patients.
- Purity: 99.97%
- CAS No.: 1481636-41-2
- Formula: C34H66O4
- Molecular Weight:538.89
-
Storage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Purity & Documentation
- References
-
Help & FAQs
-
Immunology/Inflammation Compound Library
HY-L007
-
Metabolism/Protease Compound Library
HY-L012
-
Anti-diabetic Compound Library
HY-L040
-
Lipid Compound Library
HY-L043
-
Ferroptosis Compound Library
HY-L051
-
Orally Active Compound Library
HY-L061
-
Neuroprotective Compound Library
HY-L070
-
Human Metabolite Library
HY-L123
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Bioactive Compound Library
HY-L001
-
High-Throughput Bioactive Compound Library
HY-L205
-
Natural Product Diversity Scaffold Library
HY-L245
All Endogenous Metabolite Isoforms
More
Biological Activity
5-PAHSA (30 μM, 12 h) reduces the levels of ROS and induces autophagy in PC12 cells[1].
5-PAHSA (20 μM, 2 days) reduces high insulin- and TNF-α-induced insulin resistance in HepG2 cells and 3T3-L1 cells[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
5-PAHSA (45 mg/kg, oral gavage, 3 days) stimulates De novo lipogenesis and lipid remodeling in epididymal WAT (eWAT) during cold exposure in mice[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
CAS No. 1481636-41-2
-
Appearance Solid
-
Molecular Weight 538.89
-
Formula C34H66O4
-
Color White to off-white
-
SMILES
OC(CCCC(CCCCCCCCCCCCC)OC(CCCCCCCCCCCCCCC)=O)=O
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Solvent & Solubility
DMSO : 16.67 mg/mL (30.93 mM; ultrasonic and warming and heat to 80°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: 1.67 mg/mL (3.10 mM); Clear solution; Need ultrasonic
This protocol yields a clear solution of 1.67 mg/mL.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (16.7 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation
-
Data Sheet (267 KB)
-
SDS (647 KB)
- English - EN (647 KB)
- Français - FR (647 KB)
- Deutsch - DE (647 KB)
- Norwegian - NO (647 KB)
- Español - ES (647 KB)
- Swedish - SV (647 KB)
- Italian - IT (647 KB)
- Korean - KR (647 KB)
- Portuguese - PT (647 KB)
-
Handling Instructions (2659 KB)
References
[1]. Wang JT, et al. A novel palmitic acid hydroxy stearic acid (5-PAHSA) plays a neuroprotective role by inhibiting phosphorylation of the m-TOR-ULK1 pathway and regulating autophagy. CNS Neurosci Ther. 2021 Apr;27(4):484-496. [Content Brief]
[2]. Paluchova V, et al. Lipokine 5-PAHSA Is Regulated by Adipose Triglyceride Lipase and Primes Adipocytes for De Novo Lipogenesis in Mice. Diabetes. 2020 Mar;69(3):300-312. [Content Brief]
[3]. Wang YM, et al. High Glucose Concentration Impairs 5-PAHSA Activity by Inhibiting AMP-Activated Protein Kinase Activation and Promoting Nuclear Factor-Kappa-B-Mediated Inflammation. Front Pharmacol. 2019 Jan 7;9:1491. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 1.8557 mL | 9.2783 mL | 18.5567 mL | 46.3917 mL |
| 5 mM | 0.3711 mL | 1.8557 mL | 3.7113 mL | 9.2783 mL | |
| 10 mM | 0.1856 mL | 0.9278 mL | 1.8557 mL | 4.6392 mL | |
| 15 mM | 0.1237 mL | 0.6186 mL | 1.2371 mL | 3.0928 mL | |
| 20 mM | 0.0928 mL | 0.4639 mL | 0.9278 mL | 2.3196 mL | |
| 25 mM | 0.0742 mL | 0.3711 mL | 0.7423 mL | 1.8557 mL | |
| 30 mM | 0.0619 mL | 0.3093 mL | 0.6186 mL | 1.5464 mL |
5-PAHSA Related Classifications
HY-116193 Related Classifications
Powered by Bioz